Recursion Pharmaceuticals (RXRX) Reports Q1 Loss, Misses Revenue Estimates

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.50 per share versus the Zacks Consensus Estimate of a loss of$ 0.44. This compares to loss of $0.39 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -13.64%. A quarter ago, it was expected that this biotechnology company would post a loss of$ 0.36 per share when it actually produced a loss of $0.53, delivering a surprise of -47.22%.Over the last four quarters ...